6,678 trials
Peripheral Arterial Occlusive Disease
Primary: Level of Pain in the Lower Extremities Scored by the Participants on the Visual Analog Scale Following Intraarterial Administration of ISOVUE-250 or VISIPAQUE 270 in…
Hypercholesterolemia
Primary: Fecal Excretion of Plasma-derived Cholesterol — 1593; 1950 mg/day cholesterol excreted — p=0.019
Childhood Schizophrenia · Psychotic Disorder · Schizophrenia
Primary: Change in the Scale for the Assessment of Negative Symptoms — -14; -25 Scores on a scale — p=.04
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in IAUC (Incremental Area Under the Curve) for Postprandial Glucose (0-4 Hours) Over 3 Main Meals — -1.99; -1.977 mmol/L
Exercise-induced Bronchoconstriction (EIB)
Primary: Maximum Percent Fall in Forced Expiratory Volume in 1 Second (FEV1) After Exercise Challenge at 2 Hours Postdose — 15.35; 20.00 Percent fall in FEV1 — p=0.020
Obstructive Defecation Syndrome · Chronic Constipation · Rectocele
Primary: Percentage of Change (Reduction) in Total ODS Symptom Composite Score From Baseline to One Year Post Procedure — 60.8 percentage of change
Pertussis · Diphtheria · Tetanus
Primary: Number of Participants Reporting a Solicited Local or Systemic Reaction Post-Vaccination With Either REPEVAX® or COVAXIS® Vaccine — 89; 87; 85; 87 Participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c at Week 80 — 8.64; 8.64; -1.36; -1.85 percent change — p=<0.0001
Bipolar Depression
Primary: Modified Bond-Lader Visual Analog Scale Score After 50-mg Dose (Day 2) — 45.022; 32.472 units on scale
Myopia
Primary: Any Slit Lamp Finding > Grade 2 — 2; 5; 10 Eyes
Sleep Disorders · Obstructive Sleep Apnea · Major Depressive Disorder
Primary: Change From Baseline on Maintenance of Wakefulness Test (MWT) to Endpoint (12 Weeks or Last Observation After Baseline) — 2.6; 1.1 Minutes — p=0.3043
Hypertension
Primary: Mean 24 Hour Ambulatory Systolic Blood Pressure (MASBP) in Systolic Hypertensive Patients Treated With Aliskiren (300 mg) for 4 Weeks on a High Sodium Diet Versus 4…
Renal Transplant
Primary: Mycophenolic Acid (MPA) Maintenance Treatment — 47.06; 16.39 Percentage of Patients
Alzheimer's Disease
Primary: Percentage of Patients Who Had a Gastrointestinal Adverse Event (AE) at Any Time During the Study — 4.65; 4.26; 6.12 Percentage of participants
Dry Eye
Primary: Ocular Comfort Level From Baseline to End of Study — 0.68; 0.84; 0.24; 0.31 Units on a scale